SecBot SecBot
SECBOTREPLAY Home › Report › QURE

QURE · uniQure priced a $225M underwritten public offering of 4,945,055…

uniQure N.V. · 424B5 filed Jun 24, 2026 at 16:52 ET

At the news

MIXEDIMPACT 6/10

424B5 filed Jun 24, 2026 at 16:52 ET

uniQure priced a $225M underwritten public offering of 4,945,055 ordinary shares at $45.50/share, a ~7.2% discount to the prior close of $49.04. Net proceeds of ~$211M will fund commercialization readiness, a confirmatory study for lead gene therapy AMT-130 (Huntington's disease), and pipeline development. The offering comes days after the company announced FDA alignment to accept Phase I/II data as the primary basis for a BLA submission under accelerated approval, a major regulatory de-risking event. The 7.8% dilution (4.95M new shares vs 63.0M outstanding) is a near-term overhang, but the capital raise removes a key financing overhang and funds the path to a pivotal BLA filing in Q3 2026.

  • Offering of 4,945,055 ordinary shares at $45.50/share, raising ~$225M gross / ~$211M net proceeds
  • Underwriters have a 30-day option to purchase up to an additional 741,758 shares
  • Public offering price represents a ~7.2% discount to the June 23, 2026 close of $49.04
  • Post-offering shares outstanding: 67,978,304 (68,720,062 if underwriters exercise option in full), a ~7.8% increase from 63,033,249

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access